Vir Biotechnology, Inc. VIR Excess funds payable under grant agreements
Other financials
Where this comes from
Reported directly by Vir Biotechnology, Inc. in its filing.
Tagged under the XBRL concept vir:ExcessFundsPayableUnderGrantAgreementsCurrent.
The official record: Vir Biotechnology, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Vir Biotechnology, Inc.'s excess funds payable under grant agreements.
Connect your AI assistant and see it in context, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Vir Biotechnology, Inc.'s excess funds payable under grant agreements?
- Vir Biotechnology, Inc. (VIR) reported excess funds payable under grant agreements of $1.83M in Q1 2026.
- How has Vir Biotechnology, Inc.'s excess funds payable under grant agreements changed year-over-year?
- Vir Biotechnology, Inc.'s excess funds payable under grant agreements decreased by 83.6% year-over-year, from $11.18M to $1.83M.
- What is the long-term trend for Vir Biotechnology, Inc.'s excess funds payable under grant agreements?
- Over 3 years (2022 to 2025), Vir Biotechnology, Inc.'s excess funds payable under grant agreements has grown at a -38.0% compound annual growth rate (CAGR), from $7.65M to $1.83M.